益生菌补充剂在预防早产婴儿死性肠球炎的有效性:系统性审查和元分析
Abdihafid Mohamed Abdullahi1, Shuangkui Zhao1, Yanping Xu1
1Department of NICU, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
概括
益生菌补充Bifidobacterium bifidum G001 (BBG001) 显著降低了早产婴儿死性肠球炎 (NEC) 和败血症的发生. 需要进一步的研究来证实BBG001的存在.
科学领域:
- 新生儿医学 新生儿医学
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 结核性肠球炎 (NEC) 是早产婴儿的一种严重疾病,其特点是肠道炎症和细菌入侵,导致显著的发病率和死亡率.
- 益生菌通过调节肠道微生物群来减轻NEC的潜力已得到承认,但Bifidobacterium bifidum G001 (BBG001) 的特定疗效仍然不清楚.
研究的目的:
- 评估BBG001与安慰剂相比在预防NEC,晚发性败血症和早产婴儿全因死亡方面的有效性.
- 综合随机对照试验 (RCT) 的证据,以评估BBG001对新生儿结局的影响.
主要方法:
- 按照PRISMA指南进行了系统审查和元分析,包括2014年至2024年间发表的RCT.
- 包括涉及早产婴儿 (<37周妊娠或<2500克出生体重) 接受肠道BBG001与安慰剂的研究. 结果包括NEC (≥II期),晚发性败血症和全因死亡率.
主要成果:
- 与7180名婴儿进行的9项研究表明,BBG001显著降低了NEC阶段>2 (OR=0.66),死亡率和发病率 (OR=0.74),以及败血症 (OR=0.71).
- BBG001还降低了周心室白血病 (OR=0.61) 和心室内出血 (OR=0.48) 的发生率,并减少了与感染有关的死亡 (OR=0.80).
结论:
- BBG001补充剂在降低NEC发病率,血液感染和早产婴儿感染相关死亡率方面表现出有效性.
- 虽然结果很有希望,但建议进行进一步的大规模RCT,以巩固BBG001在新生儿护理中的作用,因为研究设计的可变性.
相关概念视频
01:22Probiotics
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
01:30Development of Human Microbiota
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...